NewsBite

Property developer Lang Walker's biotechnology investment secrets

Jessica Gardner
Jessica GardnerUnited States correspondent
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Lang Walker reckons he is yet to have his greatest success investing in biotechnology companies, but he has no problem identifying his biggest failure: the $10 million he lost backing a novel pain-relief drug.

The demise of QRxPharma in 2014 pitted Walker and his ally, fund manager Allan Gray, against a board with biotechnology royalty including ResMed chairman Peter Farrell and venture capitalist Michael Quinn.

Loading...
Jessica Gardner is The Australian Financial Review’s United States correspondent. She was previously deputy editor - news. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

License article

Read More

Latest In Healthcare & fitness

Fetching latest articles

Most Viewed In Companies

    The Australian Financial Review Magazine

    Vince Frost

    BOSS Financial Review

    Hayden Brass

    Life & Leisure

    Nicole Car as Rusalka in the Opera Conference production of Dvorak’s fairytale opera.

    Rich List

    AFRmag Covers

    Original URL: https://www.afr.com/companies/healthcare-and-fitness/property-developer-lang-walkers-biotechnology-investment-secrets-20161220-gtf1pw